PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 86070

Title: SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis in COVID-19-Infected Patients, A Systematic Review of Case Reports

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03302683

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Chief Physician, Director, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2023-05-29

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-06-09 01:57

Reviewer performed review: 2023-06-10 05:59

Review time: 1 Day and 4 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [Y] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [Y] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This manuscript submitted by Khedr A and co-workers investigated the outcomes and treatment of euglycemic diabetic ketoacidosis in COVID-19-infected diabetic patients taking SGLT2 inhibitors. Despite of some clinical interests, there was no in-depth analysis of the clinical features of the study population. Furthermore, the number of literatures and cases included in this systematic review was too few to conduct a sufficient meta-analysis and draw any definitive conclusions.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 86070

Title: SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis in COVID-19-Infected Patients, A Systematic Review of Case Reports

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02624393

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Spain

Author's Country/Territory: United States

Manuscript submission date: 2023-05-29

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-06-09 07:53

Reviewer performed review: 2023-06-12 09:17

Review time: 3 Days and 1 Hour

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [ ] Anonymous [Y] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The paper from Khedar A. et al describes cases and a meta-analysis of euglycemic ketoacidosis (eu-DKA) in diabetes mellitus patients treated with SGLT2inhibitors and infected by SARS-COV-2. The paper is well written, the methodolgy used is adequate and the results, discussion and conclusions are well conducted. MAJOR CONCERN: The authors describe eu-DKA (pg 11), as "severe metabolic acidosis despite normal glucose level", but in pg 9 they affirm that the glucose level of the patients was situated between 113 and 286 mg/dL. Therefore you can talk about DKA and not about eu-DKA. Can you clarify this apparent controversy ?. As the authors recognised as a limitation in the discussion, the number of patients is very low in the current literature. I do not have MINOR concerns.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 86070

Title: SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis in COVID-19-Infected Patients, A Systematic Review of Case Reports

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02602042

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor, Dean, Deputy Director, Research Scientist

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2023-05-29

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-06-15 03:10

Reviewer performed review: 2023-06-15 03:42

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This review has an interesting topic. Authors elaborated the association between SGLT2 inhibitors and eu-DKA in diabetic patients with COVID-19. The results of this review can cause us to concern that SGLT2is might be used with great caution in COVID-19-infected diabetic patients. The article has delivered important clinical message and should be of great interest to the readers. The submission is worthy of publication.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 86070

Title: SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis in COVID-19-Infected Patients, A Systematic Review of Case Reports

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03352142

Position: Editorial Board

Academic degree: PhD

Professional title: Full Professor, Statistician

Reviewer's Country/Territory: Iran

Author's Country/Territory: United States

Manuscript submission date: 2023-05-29

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-06-15 16:43

Reviewer performed review: 2023-06-17 13:12

Review time: 1 Day and 20 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The following points about this systematic review on case report conducted for investigating SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis in COVID-19-Infected Patients are suggested 1.   Objective in abstract should be presented more clearly and completely. 2. How you included unpublished studies in your review? which key terms you focused on? 3.   You wrote in results of abstract "…eight studies, encompassing a cohort of twelve patients…" how about other seven studies? Please revise and rewritten results; the results are not based on all studies. 4.It is expected to review with details the content of case report studies you included in your review in introduction section. 5.   How about the inclusion and exclusion criteria? 6. Please declare the PICO of your systematic review   7.Please refer to your search strategy in your methods section for those you appended at the end of manuscript.   8. How about the quality assessment, it is advisable to do it based on CARE checklist.   You did it based on JBI , however where its results. 9. Please present the key elements of each of the terms you mentioned them in the following sentence ". Information extracted from the articles included demographic background, comorbidities, disease onset, initial

symptoms, laboratory tests, diabetes mellitus type, SGLT2 inhibitor type, study date, study design, treatment intervention, and case outcomes." 10. What do you mean from study design , all included studies in your sys review are case report ?!! 11. Diabetes mellitus type?! 12. Results: I see the sentence "We identified a total of eight studies, encompassing a cohort of twelve patients…" in abstract however I see other completely different sentence in main results section as "…including the United States (n=3), the United Kingdom (n=5), Brazil (n=1), Malaysia (n=1), and Belgium (n=2). "what do you mean from a cohort of patients consists of 12 ??? 13. The studies in this sentence "…including the United States (n=3), the United Kingdom (n=5), Brazil (n=1), Malaysia (n=1), and Belgium (n=2)." Should be referenced with their own reference number. 14.

I see the following sentence "Out of the 12 patients, 11 had a favorable outcome and recovered" I results section; first :what is your sys review 's outcome? Second : what is the meaning of favorable? It should be declared in PICO ; Third: when I see the table 1 content , some (more than 1) did not report outcome? 15. Generally your manuscript structure and content have not been organized in a way to infer clear conclusion with some big ambiguities as stated particularly in points no:12-14.